


CLAIMS:

1. A compound of formula (I) or a pharmaceutically acceptable salt thereof:



wherein:

R^1 represents branched C_{3-6} alkyl, C_{3-5} cycloalkyl or $-C_{1-4}$ alkyl C_{3-4} cycloalkyl;

R^2 represents halogen, C_{1-6} alkyl, C_{1-6} alkoxy, cyano, amino or trifluoromethyl;

n represents 0, 1 or 2;

R^3 represents $-X$ -aryl, $-X$ -heteroaryl, $-X$ -heterocyclyl, $-X$ -aryl-aryl, $-X$ -aryl-heteroaryl, $-X$ -aryl-heterocyclyl, $-X$ -heteroaryl-aryl, $-X$ -heteroaryl-heteroaryl, $-X$ -heteroaryl-heterocyclyl, $-X$ -heterocyclyl-aryl, $-X$ -heterocyclyl-heteroaryl or $-X$ -heterocyclyl-heterocyclyl;

such that when R^3 represents $-X$ -piperidinyl, $-X$ -piperidinyl-aryl, $-X$ -piperidinyl-heteroaryl or $-X$ -piperidinyl-heterocyclyl said piperidinyl group is attached to X via a nitrogen atom;

wherein R^3 is attached to the phenyl group of formula (I) at the 3 or 4 position;

X represents a bond, O, CO, SO_2 , CH_2O , OCH_2 , NR^4 , NR^4CO or C_{1-6} alkyl;

R^4 represents hydrogen or C_{1-6} alkyl;

wherein said aryl, heteroaryl or heterocyclyl groups of R^3 may be optionally substituted by one or more (e.g. 1, 2 or 3) halogen, hydroxy, cyano, nitro, oxo, halo C_{1-6} alkyl, halo C_{1-6}

alkoxy, C_{1-6} alkyl, C_{1-6} alkoxy, aryl C_{1-6} alkoxy, C_{1-6} alkylthio, C_{1-6} alkoxy C_{1-6} alkyl, C_{3-7} cycloalkyl C_{1-6} alkoxy, C_{3-7} cycloalkylcarbonyl, $-COC_{1-6}$ alkyl, C_{1-6} alkoxy C_{1-6} alkyl, C_{1-6} alkyl, heteroaryl C_{1-6} alkyl, heterocyclyl C_{1-6} alkyl, C_{1-6} alkylsulfonyl, C_{1-6} alkylsulfinyl, C_{1-6} alkylsulfonyloxy, C_{1-6} alkylsulfonyl C_{1-6} alkyl, arylsulfonyl, arylsulfonyloxy, arylsulfonyl C_{1-6} alkyl, aryloxy, $-CO$ -aryl, $-CO$ -heterocyclyl, $-CO$ -heteroaryl, C_{1-6} alkylsulfonamido C_{1-6} alkyl,

C_{1-6} alkylamido C_{1-6} alkyl, arylsulfonamido, arylaminosulfonyl, arylsulfonamido C_{1-6} alkyl, arylcarboxamido C_{1-6} alkyl, aroyl C_{1-6} alkyl, aryl C_{1-6} alkanoyl, or a group $NR^{15}R^{16}$, $-NR^{15}CO$ -aryl, $-NR^{15}CO$ -heterocyclyl, $-NR^{15}CO$ -heteroaryl, $-CONR^{15}R^{16}$, $-NR^{15}COR^{16}$, $-NR^{15}SO_2R^{16}$ or $-SO_2NR^{15}R^{16}$ groups, wherein R^{15} and R^{16} independently represent hydrogen or C_{1-6} alkyl;

or solvates thereof.

2. A compound according to claim 1 which is a compound of formula E1-E58 or a pharmaceutically acceptable salt thereof.

3. A pharmaceutical composition which comprises the compound of formula (I) as defined in claim 1 or claim 2 or a pharmaceutically acceptable salt thereof and a pharmaceutically acceptable carrier or excipient.

4. A compound as defined in claim 1 or claim 2 for use in therapy.
5. A compound as defined in claim 1 or claim 2 for use in the treatment of neurological diseases.
- 5 6. Use of a compound as defined in claim 1 or claim 2 in the manufacture of a medicament for the treatment of neurological diseases.
- 10 7. A method of treatment of neurological diseases which comprises administering to a host in need thereof an effective amount of a compound of formula (I) as defined in claim 1 or claim 2 or a pharmaceutically acceptable salt thereof.
- 15 8. A pharmaceutical composition for use in the treatment of neurological diseases which comprises the compound of formula (I) as defined in claim 1 or claim 2 or a pharmaceutically acceptable salt thereof and a pharmaceutically acceptable carrier.